Elsevier

The Lancet

Volume 383, Issue 9918, 22–28 February 2014, Page 669
The Lancet

Editorial
Statins for millions more?

https://doi.org/10.1016/S0140-6736(14)60240-3Get rights and content

References (0)

Cited by (20)

  • Statins and autoimmunity

    2015, Medicina Clinica
  • The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013

    2015, Health Policy
    Citation Excerpt :

    Such evidence has had major implications for dyslipidemia management and prevention. Evolving clinical guidelines and recommendations naturally result in the still higher number of patients eligible for statin therapy which further increases the size of the already enormous market [3–5]. In order to control increasing public health care spending, namely in pharmaceuticals, European countries develop and employ various cost containment policies, namely in pricing and reimbursement regulation [6,7].

View all citing articles on Scopus
View full text